A PHASE II OPEN LABEL STUDY OF NEIHULIZUMAB, AN ANTI-CD162 (PSGL-1) ANTIBODY, IN PATIENTS WITH MODERATE TO SEVERE ACTIVE, ANTI-TNFα AND/OR ANTI-INTEGRIN REFRACTORY ULCERATIVE COLITIS

neihulizumab (ALTB-168) - AltruBio

David Rubin; Scott D Lee; Lucky Flores; Gustavo Albizu-Angulo; Ellen Scherl; Surinder Saini; Iming Cho; Shih-Yao Lin; Simona Reed; Jesse Hall

Dec 23, 2022